Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Disc Medicine's Bitopertin?
Bitopertin is a small molecule commercialized by Disc Medicine, with a leading Phase III program in Porphyria (Erythropoietic Protoporphyri). According...
Data Insights
Bitopertin by Disc Medicine for Porphyria (Erythropoietic Protoporphyri): Likelihood of Approval
Bitopertin is under clinical development by Disc Medicine and currently in Phase III for Porphyria (Erythropoietic Protoporphyri). According to GlobalData,...